Skip to content
    EBS
    Earnings call· Jun 2026(Q2 FY26)

    Emergent BioSolutions Q2 FY26 earnings call EBS

    Aug 5, 2026 Source

    Executive summary

    Emergent BioSolutions Q2 FY26 — Strong MCM Performance Offsets Naloxone Headwinds

    Emergent BioSolutions delivered strong Q2 FY26 results, exceeding revenue and adjusted EBITDA expectations, primarily driven by accelerated Medical Countermeasures (MCM) deliveries and contract awards. However, the company faces significant headwinds in its naloxone business due to increased competition and pricing pressure, leading to a downward revision of full-year revenue and profitability guidance. Management is implementing restructuring actions to improve cost structure and is reorienting R&D and business development to focus on high-return opportunities and address evolving public health threats.

    Highlights

    5

    • Q2 revenue of $234 million significantly exceeded the high end of prior guidance ($185 million)

    • Q2 adjusted EBITDA of $97 million, representing a 41% margin, up from 23% in Q2 2025

    • MCM revenue was $168 million in Q2, the highest second quarter revenue since 2020, driven by accelerated deliveries and contract awards

    • Secured over 10 contract awards year-to-date, including a $52.7 million modification for ACAM2000 and $64.5 million for botulism anti-toxin

    • Ended Q2 with $140 million of cash and $190 million of total liquidity, with an additional $145 million collected in July from accounts receivable

    Concerns

    5

    • Full-year 2026 revenue guidance revised down to $645 million-$675 million from $720 million-$760 million due to lower commercial revenue

    • Naloxone market experiencing increased competitive intensity, new entrants, and aggressive pricing pressures

    • Recorded a noncash impairment charge of approximately $191 million related to the NARCAN asset group due to updated market assessment

    • Adjusted EBITDA guidance revised down to $130 million-$150 million from $155 million-$175 million

    • GAAP net loss guidance widened to negative $245 million to negative $225 million, reflecting the impairment and restructuring costs

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year 2026 Total Revenue
    $645 million to $675 million
    high materiality
    High
    Full-year 2026 GAAP Net Loss
    negative $245 million to negative $225 million
    high materiality
    High
    Full-year 2026 Adjusted Net Income
    $10 million to $30 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $130 million to $150 million
    high materiality
    High
    Full-year 2026 Adjusted Gross Margin
    42% to 44%
    medium materiality
    High
    Q3 2026 Total Revenue
    $110 million to $130 million
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Medical Countermeasures (MCM)
    Highest second quarter revenue since 2020, driven by accelerated deliveries and contract activity related to ACAM and BAT. Strong execution with U.S. and international government customers.
    International sales: 20% of total first half 2026 MCM revenues
    		$168 million———
    Commercial (Naloxone)
    Reflects NARCAN's market leadership position, but year-over-year performance was affected by new competitive pressure and continued pricing and volume dynamics. Lower overall commercial revenue is expected for the balance of the year.
    Market share: >50% of the naloxone market
    		————

    Operational metrics

    20
    Adjusted EBITDA
    $97 millionup from $33 million in Q2 FY25
    Q2 FY26

    Exceeded internal expectations and analyst consensus.

    Adjusted EBITDA
    $132 millionup from $112 million in YTD FY25
    YTD FY26

    Reflects strong year-to-date performance.

    Adjusted Gross Margin
    58%up from 49% in Q2 FY25
    Q2 FY26

    Improved due to favorable product mix and volume.

    Adjusted Gross Margin
    56%up 100 bps year-over-year
    YTD FY26

    Reflecting the benefit of product mix and disciplined operational execution.

    Operating Expenses
    $54 milliondown approximately $2 million year-over-year
    Q2 FY26

    Demonstrates continued cost discipline across the business.

    Cash and Cash Equivalents
    $140 million
    Q2 FY26

    Maintained a solid cash position while absorbing a $50 million investment milestone payment.

    Total Liquidity
    $190 million
    Q2 FY26

    Includes cash and available credit.

    Accounts Receivable Collection
    $145 million
    July 2026

    Collected in early Q3, further improving operating cash flow and liquidity.

    Gross Debt
    $590 millioncompared with $700 million in Q2 FY25
    Q2 FY26

    Reduced year-over-year.

    Net Debt
    $450 million
    Q2 FY26

    Calculated as gross debt minus cash.

    Net Leverage Ratio
    1.9xstable year-over-year
    Q2 FY26

    Remained stable.

    NARCAN Noncash Impairment Charge
    $191 million
    Q2 FY26

    Reflects updated assessment of NARCAN's expected future cash flows due to increased competitive landscape. Noncash charge, does not affect cash, liquidity, operating cash flow, or adjusted EBITDA.

    Restructuring Annualized Savings
    $40 million
    Annualized

    Expected from workforce reduction, lab closures, office building sale, and warehouse lease exit. Partially offset by approximately $11 million of cost to achieve.

    Office Building Sale
    $6.4 million
    Q2 FY26

    Sale of an unutilized office building in Gaithersburg, Maryland.

    Debt Repurchase Program Authorization
    $75 million
    Ongoing

    Authorized by the Board to repurchase senior unsecured notes.

    Share Repurchase Program Authorization
    $50 million
    Through March 2027

    Ongoing program.

    Shares Repurchased
    1.1 million shares
    Q2 FY26

    Executed during the quarter.

    Shares Repurchased
    1.9 million shares
    YTD FY26

    Year-to-date repurchases.

    Remaining Share Repurchase Authorization
    $37.5 million
    Q2 FY26

    Amount remaining under the authorized share repurchase program.

    Ebanga Investment Milestone Payment
    $50 million
    Q2 FY26

    Absorbed during the quarter, impacting cash balance.

    Industry KPIs

    3
    MetricValueDetails
    Pipeline read out calendarMOSA study for TEMBEXA
    Regulatory approvals filingsACAM2000
    Therapeutic drug market share>50%%

    Deals & partnerships

    1
    AI leaders and partnersCollaboration to address bioterrorism risks and improve biodefense preparedness

    Seeking to collaborate with AI leaders and partners to address the potential risk of bioterrorism and improve biodefense response preparedness, especially concerning AI's potential misuse to create new pathogens.

    Risks & headwinds

    4
    Increased competitive pressure in naloxone marketNear- to medium-term

    Two new nasal naloxone entrants, including a new 4mg OTC approval on June 16, 2026, and a 10mg prescription agent launching in August 2026. Aggressive pricing across the naloxone segment.

    Mitigation: Implementing restructuring actions to improve cost structure, focusing on NARCAN brand recognition, and introducing new innovations like carrying cases and multipacks.

    Lower commercial revenue outlookH2 FY26

    Full-year 2026 revenue guidance revised down by $75 million at midpoint (from $740M to $660M).

    Mitigation: Cost savings initiatives and continued operating expense discipline partially offset the impact on adjusted EBITDA.

    Potential misuse of AI for bioterrorismOngoing

    AI could be utilized by bad actors to create new pathogens that could be very, very chaotic and cause additional problems.

    Mitigation: Seeking to collaborate with AI leaders and partners to be front and center in helping governments prepare for potential activities.

    Ebola virus on the riseOngoing

    Ebola virus is on the rise in Africa.

    Mitigation: Initiating a pan-Ebola therapeutic program.

    What to watch in Q3 FY26

    5

    NARCAN sales erosion/stabilization

    next quarter
    CurrentUnder pressure from new entrants and pricing
    TargetStabilization of market share and pricing, or impact of new product configurations

    Why it matters

    The naloxone market dynamics are a key driver of the revised full-year guidance and the noncash impairment charge, impacting commercial revenue and overall profitability.

    As market dynamics change, we need to proactively get ahead of these issues.

    Q&A highlights

    6

    What initiatives will slow NARCAN sales erosion and leverage brand recognition against next-gen fentanyl analogs?

    Management is focusing on the strong NARCAN brand name, introducing new innovations like carrying cases and multipacks for high-volume users, and wall kits. They acknowledge competitive pricing pressures from new entrants but believe NARCAN will remain the 'gold standard' and aim to maintain market leadership.

    “We're looking at, obviously, number one, the brand NARCAN itself is important. We have that brand name when you are looking at the opportunities that face the marketplace, having the brand name NARCAN is very important and we've had a chance to talk to consumers about that. They obviously recognize the importance of the NARCAN brand name.”

    asked by Raghuram Selvaraju · answered by Joseph Papa

    2 min read6 chapters

    Detailed Narrative

    01

    Multiyear Transformation and Strategic Reorientation

    Emergent is executing a multiyear transformation plan focused on improving operating performance, advancing strategic transformation for long-term growth and profitability, identifying growth opportunities, and strengthening the balance sheet. The company is unifying R&D and business development into a single 'growth organization' to enable faster, more informed portfolio decisions and better capital allocation, aiming for improved return on investment for shareholders.

    02

    Naloxone Market Dynamics and Competitive Pressure

    The naloxone market, particularly for NARCAN, is experiencing significant changes due to the entry of two new nasal naloxone products, including a new 4mg OTC approval and a 10mg prescription agent. This has led to increased competitive intensity and aggressive pricing pressures. While Emergent maintains market leadership with over 50% share, the company anticipates continued price erosion and has adjusted its commercial revenue outlook accordingly, despite ongoing efforts to innovate with new product configurations like carrying cases and multipacks.

    03

    Restructuring Actions and Cost Savings

    To align resources with current business realities and prepare for 2027 and beyond, Emergent is implementing several restructuring actions. These include a reduction of approximately 90 positions, closure of two wet laboratories in Maryland, sale of an unutilized office building for $6.4 million, and exiting a central warehouse lease. These efforts are expected to yield annualized savings of approximately $40 million, with the full run rate realized in 2027.

    04

    Strong Q2 Performance and MCM Business Strength

    Emergent delivered strong second-quarter results, with revenue of $234 million significantly exceeding guidance and adjusted EBITDA of $97 million (41% margin). This performance was primarily driven by the Medical Countermeasures (MCM) segment, which recorded $168 million in Q2 revenue, the highest since 2020. The company secured multiple U.S. government contract awards, including $52.7 million for ACAM2000 and $64.5 million for botulism anti-toxin, and saw international MCM sales represent 20% of total first-half MCM revenues.

    05

    Capital Allocation and Financial Flexibility

    The company ended Q2 with $140 million in cash and $190 million in total liquidity, with an additional $145 million in accounts receivable collected in July. Gross debt was reduced to $590 million, and net leverage remained stable at 1.9x. Emergent completed a term loan refinancing, extending maturities to 2031 and reducing interest rates. A new $75 million debt repurchase program for senior unsecured notes was authorized, and the company repurchased $9 million in shares during Q2, with $37.5 million remaining under the share repurchase program.

    06

    Addressing Biodefense and Public Health Threats

    Emergent continues to focus on its mission to protect and save lives, supporting governments with critical products and capabilities. The company is initiating a pan-Ebola therapeutic program and advanced regulatory activities for ACAM2000 (Saudi FDA approval, Singapore HSA approval for mpox indication). Emergent is also seeking to collaborate with AI leaders to address the potential risk of bioterrorism and improve biodefense preparedness, responding to concerns about AI's potential misuse in creating new pathogens.

    AI-generated summary of the company’s earnings call. Not investment advice.